OBJECTIVES:   Chemotherapy-induced adverse events, such as neutropenia, for metastatic non-small cell lung cancer (mNSCLC) can result in the need for supportive care (SC) services.  This study evaluated differences in the utilization and cost of SC services among mNSCLC patients treated with nab-paclitaxel+carboplatin (nab-P/C) and sb-paclitaxel+carboplatin (sb-P/C). METHODS: Patients with mNSCLC were abstracted retrospectively from Marketscan Commercial and Medicare claims databases during 2012-2014. Patients (≥18 years) with mNSCLC receiving > 2 doses of nab-P/C or sb-P/C as first line between 1/1/2013-12/1/2014 and ≥ 30 days of follow-up were included.  SC utilization was abstracted which included granulocyte-colony stimulating factor (G-CSF), erythropoietin, fluids and electrolytes (F&E), anti-emetics, and other interventional SC therapies.  The utilization and monthly cost per patient of SC services received during first line therapy were compared.  RESULTS: A total of 131 patients received weekly nab-P/C, while 356 received sb-P/C every 3 weeks.  Patients receiving nab-P/C were older than sb-P/C (65.2 vs 61.8; p<0.001). There were no differences in gender (40% female for both, p=0.97).  Mean Charlson Comorbidity Index was statistically higher for nab-P/C cohort (9.4 vs. 9.1; p=0.03).  Similar proportion of patients utilized G-CSF in both cohorts (nab-P/C: 42%; sb-P/C: 48.3%; p=0.22); however, sb-P/C patients receiving G-CSF had more claims for G-CSF.  Patients receiving nab-P/C were less likely to receive F&E compared to sb-P/C (65% vs. 98%, p<0.001). Patients receiving nab-P/C were more likely to receive erythropoietin (26% vs. 7%; p<0.001).  Monthly SC costs were significantly lower for nab-P/C vs. sb-P/C ($2,220 vs. $3,975; p<0.001), primarily due to lower costs for G-CSF ($1,035 vs. $2,853; p=0.03) and F&E ($65 vs. $379; p<0.001).  Costs for erythropoietin (nab-P/C: $252 vs. sb-P/C: $74; p=0.16) and anti-emetics (nab­-P/C: $844 vs. sb-P/C: $660; p=0.15) were not statistically different. CONCLUSIONS: Compared to sb-P/C, patients receiving nab-P/C had lower SC costs, primarily due to lower G-CSF cost.